
  
    
      
        Introduction_NNP
        Each_DT year_NN approximately_RB 750_CD 000_CD patients_NNS in_IN the_DT USA_NNP
        suffer_VB from_IN sepsis_NN ._. Treatment_NNP for_IN this_DT disease_NN costs_NNS $_$ 16_CD ._. 7_CD
        billion_CD annually_RB [_NN 1_CD ]_NN ._. Despite_IN advances_NNS in_IN supportive_JJ
        intensive_JJ care_NN and_CC use_NN of_IN appropriate_JJ antibiotics_NNS ,_, the_DT
        mortality_NN associated_VBN with_IN sepsis_NN remains_VBZ high_JJ ,_, especially_RB
        among_IN those_DT who_WP develop_VBP hemodynamic_JJ shock_NN [_NN 2_CD 3_CD 4_CD ]_NN ._. Such_JJ
        patients_NNS frequently_RB progress_NN to_TO multiple_JJ organ_NN dysfunction_NN
        syndrome_NN ,_, which_WDT results_VBZ in_IN a_DT much_RB higher_JJR mortality_NN rate_NN
        than_IN among_IN patients_NNS who_WP do_VBP not_RB develop_VB such_JJ complications_NNS [_NN
        3_CD 5_CD 6_CD 7_CD ]_NN ._. This_DT life-threatening_JJ syndrome_NN is_VBZ largely_RB
        attributed_VBN to_TO the_DT cardiovascular_JJ abnormalities_NNS associated_VBN
        with_IN septic_JJ shock_NN ,_, requiring_VBG supportive_JJ therapy_NN (_( e_SYM ._. g_SYM ._.
        mechanical_JJ ventilation_NN ,_, fluid_JJ resuscitation_NN ,_, and_CC
        vasopressors_NNS )_) with_IN volume_NN loading_NN ,_, oxygen_NN delivery_NN ,_, and_CC
        regional_JJ perfusion_NN [_NN 8_CD ]_NN ._. However_RB ,_, there_EX are_VBP still_RB many_JJ
        controversies_NNS regarding_VBG choice_NN of_IN fluids_NNS [_NN 9_CD 10_CD 11_CD 12_CD ]_NN ,_,
        vasopressors_NNS [_NN 13_CD 14_CD 15_CD ]_NN ,_, hemodynamic_JJ end-points_JJ for_IN
        resuscitation_NN [_NN 16_CD 17_CD 18_CD 19_CD 20_CD ]_NN ,_, and_CC monitoring_VBG
        techniques_NNS ._. Findings_NNP from_IN a_DT national_JJ survey_NN of_IN intensive_JJ
        care_NN unit_NN (_( ICU_NNP )_) utilization_NN showed_VBD differences_NNS in_IN types_NNS of_IN
        procedures_NNS performed_VBN between_IN unit_NN types_NNS and_CC hospital_NN sizes_NNS
        [_NN 21_CD ]_NN ._.
        The_DT goals_NNS of_IN the_DT present_JJ study_NN were_VBD to_TO examine_VB
        systematically_RB the_DT variations_NNS in_IN overall_JJ resource_NN use_NN ,_,
        therapeutic_JJ modality_NN use_NN ,_, and_CC outcome_NN in_IN patients_NNS with_IN
        severe_JJ sepsis_NN across_IN academic_JJ medical_JJ centers_NNS ,_, and_CC to_TO
        evaluate_VB relationships_NNS between_IN therapeutic_JJ modality_NN use_NN and_CC
        variation_NN in_IN resource_NN use_NN ._.
      
      
        Methods_NNP
        
          Patient_NNP population_NN
          All_DT participating_VBG centers_NNS were_VBD members_NNS of_IN the_DT Academic_NNP
          Medical_NNP Center_NNP Consortium_NNP ,_, which_WDT sponsored_VBD the_DT study_NN ._. All_DT
          eight_CD centers_NNS were_VBD large_JJ tertiary_JJ care_NN academic_JJ medical_JJ
          centers_NNS with_IN approximately_RB 18_CD 800_CD -_: 43_CD 700_CD admissions_NNS
          annually_RB [_NN 22_CD ]_NN ._. Patient_NNP enrollment_NN occurred_VBD between_IN
          January_NNP 1993_CD and_CC April_NNP 1994_CD ._.
          Patients_NNS surveyed_VBD represented_VBD a_DT stratified_JJ random_JJ
          sample_NN of_IN patients_NNS in_IN ICUs_NNP and_CC outside_IN ICUs_NNP for_IN whom_WP
          blood_NN cultures_NNS were_VBD either_CC positive_JJ or_CC negative_JJ ,_, as_RB
          previously_RB described_VBD [_NN 22_CD ]_NN ._. Among_IN non-_NN ICU_NNP patients_NNS with_IN
          blood_NN cultures_NNS that_WDT were_VBD negative_JJ at_IN 48_CD hours_NNS ,_, sampling_VBG
          at_IN all_DT centers_NNS was_VBD fixed_VBN at_IN 10_CD %_NN ._. Among_IN ICU_NNP patients_NNS and_CC
          patients_NNS with_IN a_DT blood_NN culture_NN positive_JJ for_IN a_DT pathogen_NN
          within_IN 48_CD hours_NNS ,_, the_DT fraction_NN of_IN patients_NNS sampled_VBN was_VBD
          established_VBN at_IN each_DT center_NN and_CC varied_VBD from_IN 30_CD %_NN to_TO 60_CD %_NN ._. In_IN
          addition_NN ,_, all_DT patients_NNS who_WP died_VBD in_IN an_DT emergency_NN
          department_NN or_CC an_DT ICU_NNP and_CC all_DT patients_NNS who_WP received_VBD a_DT
          novel_NN therapy_NN for_IN sepsis_NN syndrome_NN were_VBD surveyed_VBN ._. The_DT ICUs_NNP
          involved_VBD included_VBD both_DT open_JJ and_CC closed_VBD units_NNS ._.
          Although_IN previous_JJ reports_NNS included_VBD 1342_CD episodes_NNS of_IN
          sepsis_NN among_IN 1166_CD unique_JJ patients_NNS with_IN 1190_CD hospital_NN
          admissions_NNS [_NN 22_CD 23_CD ]_NN ,_, the_DT results_NNS presented_VBN here_RB from_IN
          the_DT same_JJ database_NN were_VBD based_VBN on_IN the_DT 1011_CD (_( 87_CD %_NN )_) patients_NNS ,_,
          representing_VBG 1028_CD (_( 86_CD %_NN )_) admissions_NNS with_IN 1173_CD (_( 87_CD %_NN )_)
          episodes_NNS of_IN sepsis_NN syndrome_NN ,_, for_IN whom_WP billing_NN information_NN
          was_VBD available_JJ ._. When_WRB patients_NNS had_VBD more_JJR than_IN one_CD episode_NN in_IN
          an_DT admission_NN ,_, only_RB the_DT first_JJ episode_NN in_IN that_DT admission_NN
          was_VBD evaluated_VBN ._.
        
        
          Definitions_NNP
          Sepsis_NNP syndrome_NN was_VBD defined_VBN as_IN described_VBN by_IN Sands_NNP and_CC
          coworkers_NNS [_NN 22_CD ]_NN ,_, using_VBG a_DT modification_NN of_IN the_DT criteria_NNS
          developed_VBN by_IN Bone_NNP [_NN 24_CD ]_NN ,_, and_CC involved_VBD assessment_NN of_IN the_DT
          presence_NN of_IN both_DT screening_NN criteria_NNS and_CC confirmatory_NN
          criteria_NNS for_IN sepsis_NN syndrome_NN ._. Either_CC of_IN the_DT following_VBG
          were_VBD required_VBN for_IN a_DT patient_NN to_TO satisfy_VB the_DT screening_NN
          criteria_NNS :_: all_DT four_CD of_IN temperature_NN greater_JJR than_IN 38_CD ._. 3_LS °_NN C_NNP or_CC
          less_JJR than_IN 35_CD ._. 6_CD °_NN C_NNP rectally_RB ,_, respirations_NNS greater_JJR than_IN
          20_CD /_NN min_NN or_CC mechanical_JJ ventilation_NN ,_, heart_NN rate_NN greater_JJR than_IN
          90_CD beats_VBZ /_NN min_NN ,_, and_CC clinical_JJ evidence_NN of_IN infection_NN ;_: or_CC one_CD
          or_CC more_JJR blood_NN cultures_NNS positive_JJ for_IN a_DT pathogen_NN at_IN 48_CD
          hours_NNS following_VBG admission_NN ._. Presence_NNP of_IN any_DT of_IN the_DT
          following_VBG seven_CD features_NNS ,_, without_IN an_DT alternative_NN cause_NN ,_,
          was_VBD required_VBN for_IN satisfaction_NN of_IN the_DT confirmatory_NN
          criteria_NNS :_: ratio_NN of_IN partial_JJ arterial_NN oxygen_NN tension_NN to_TO
          inspired_VBN fractional_JJ oxygen_NN below_IN 280_CD (_( intubated_JJ )_) or_CC 40_CD %_NN
          face_NN mask_NN in_IN use_NN (_( nonintubated_JJ )_) ;_: arterial_NN pH_NN below_IN 7_CD ._. 30_CD ;_:
          urine_NN output_NN below_IN 30_CD ml_NN /_NN h_NN ;_: systolic_JJ blood_NN pressure_NN below_IN
          90_CD mmHg_NN or_CC a_DT fall_NN in_IN systolic_JJ blood_NN pressure_NN by_IN more_JJR than_IN
          40_CD mmHg_NN sustained_VBN for_IN 2_CD hours_NNS despite_IN fluid_JJ challenge_NN ;_:
          systemic_JJ vascular_NN resistance_NN below_IN 800_CD dynes_NNS ·_NN s_VBZ /_NN cm_NN 5_CD ;_:
          prothrombin_NN time_NN or_CC partial_JJ thromboplastin_NN time_NN greater_JJR
          than_IN normal_JJ or_CC platelets_NNS below_IN 100_CD ._. 0_CD ×_NN 10_CD 9_CD /_NN l_NN or_CC
          platelets_NNS decreased_VBD to_TO less_JJR than_IN 50_CD %_NN or_CC most_RBS recent_JJ
          measurement_NN before_IN current_JJ day_NN ;_: and_CC documentation_NN of_IN
          deterioration_NN in_IN mental_JJ status_NN within_IN 24_CD hours_NNS ._. In_IN
          addition_NN ,_, all_DT patients_NNS who_WP received_VBD a_DT form_NN of_IN novel_NN
          therapy_NN for_IN sepsis_NN syndrome_NN were_VBD enrolled_VBN in_IN the_DT sepsis_NN
          syndrome_NN group_NN ._. Because_IN all_DT patients_NNS with_IN sepsis_NN syndrome_NN
          also_RB meet_VB the_DT criteria_NNS for_IN '_POS severe_JJ sepsis_NN '_'' (_( the_DT term_NN that_WDT
          is_VBZ most_RBS popular_JJ now_RB )_) ,_, below_IN we_PRP use_VBP the_DT term_NN '_'' severe_JJ
          sepsis_NN '_'' ._.
          Acute_NNP respiratory_JJ distress_NN syndrome_NN (_( ARDS_NNP )_) was_VBD defined_VBN
          as_IN partial_JJ arterial_NN oxygen_NN tension_NN below_IN 50_CD mmHg_NN despite_IN
          fractional_JJ inspired_VBN oxygen_NN in_IN excess_NN of_IN 50_CD %_NN ,_, and_CC
          bilateral_JJ pulmonary_JJ infiltrates_NNS without_IN signs_NNS of_IN heart_NN
          failure_NN ._. Disseminated_NNP intravascular_NN coagulation_NN (_( DIC_NNP )_) was_VBD
          defined_VBN as_IN a_DT positive_JJ D-_NNP dimer_NN or_CC elevated_VBD fibrin_NN
          degradation_NN products_NNS plus_CC a_DT falling_VBG platelet_NN count_NN of_IN 25_CD %_NN
          of_IN less_JJR of_IN baseline_NN ,_, and_CC elevation_NN of_IN either_DT prothrombin_NN
          time_NN or_CC partial_JJ prothrombin_NN time_NN ,_, or_CC clinical_JJ evidence_NN of_IN
          bleeding_VBG ._. Central_NNP nervous_JJ system_NN (_( CNS_NNP )_) dysfunction_NN was_VBD
          defined_VBN as_IN a_DT Glasgow_NNP Coma_NNP Scale_NNP score_NN below_IN 15_CD in_IN
          patients_NNS with_IN normal_JJ results_NNS at_IN baseline_NN neurologic_JJ
          examination_NN ,_, or_CC at_IN least_JJS 1_CD point_NN lower_JJR than_IN baseline_NN in_IN
          patients_NNS with_IN a_DT previously_RB abnormal_JJ examination_NN result_NN ._.
          Renal_NNP failure_NN was_VBD defined_VBN as_IN an_DT increase_NN in_IN serum_NN
          creatinine_NN of_IN at_IN least_JJS 2_CD ._. 0_CD mg_NN /_NN dl_NN during_IN the_DT sepsis_NN
          episode_NN if_IN creatinine_NN was_VBD below_IN 1_CD ._. 5_CD mg_NN /_NN dl_NN at_IN baseline_NN ,_, or_CC
          an_DT absolute_JJ increase_NN of_IN 1_CD ._. 0_CD mg_NN /_NN dl_NN or_CC more_JJR if_IN baseline_NN
          creatinine_NN was_VBD at_IN least_JJS 1_CD ._. 5_CD ._. Liver_NNP failure_NN was_VBD defined_VBN as_IN
          present_JJ if_IN total_JJ bilirubin_NN was_VBD 2_CD ._. 0_CD mg_NN /_NN dl_NN or_CC greater_JJR ,_, and_CC
          either_CC the_DT alkaline_NN phosphatase_NN or_CC a_DT transaminase_NN level_NN
          was_VBD greater_JJR than_IN twice_RB normal_JJ ,_, in_IN the_DT absence_NN of_IN
          confounding_VBG disease_NN ._. Shock_NN (_( after_IN onset_NN of_IN sepsis_NN )_) was_VBD
          defined_VBN as_IN either_DT at_IN least_JJS 1_CD hour_NN of_IN decreased_VBD systolic_JJ
          blood_NN pressure_NN by_IN at_IN least_JJS 40_CD mmHg_NN ,_, or_CC systolic_JJ blood_NN
          pressure_NN of_IN 90_CD mmHg_NN or_CC less_JJR after_IN adequate_JJ volume_NN
          replacement_NN ,_, and_CC in_IN the_DT absence_NN of_IN antihypertensive_JJ
          agents_NNS ,_, or_CC continuous_JJ infusion_NN of_IN pressors_NNS ._. Uncontrolled_NNP
          hemorrhage_NN was_VBD defined_VBN as_IN active_JJ and_CC live-threatening_JJ
          bleeding_NN ,_, requiring_VBG transfusions_NNS of_IN more_JJR than_IN 4_CD units_NNS
          within_IN 24_CD hours_NNS of_IN onset_NN of_IN sepsis_NN ._. Moderate_NNP or_CC severe_JJ
          liver_NN disease_NN was_VBD defined_VBN as_IN cirrhosis_NNS with_IN portal_NN
          hypertension_NN ,_, or_CC hepatic_JJ failure_NN with_IN coma_NN or_CC
          encephalopathy_NN within_IN the_DT preceding_VBG 6_CD months_NNS ._.
        
        
          Data_NNP collection_NN
          Surveyors_NNP recorded_VBD the_DT presence_NN of_IN all_DT screening_NN
          criteria_NNS for_IN every_DT day_NN that_IN a_DT patient_NN was_VBD a_DT valid_JJ member_NN
          of_IN the_DT surveillance_NN group_NN ._. If_IN screening_NN criteria_NNS were_VBD
          met_VBN ,_, then_RB the_DT patient_NN was_VBD enrolled_VBN as_IN a_DT case_NN and_CC detailed_JJ
          information_NN ,_, including_VBG demographic_JJ ,_, historical_JJ ,_, clinical_JJ
          and_CC laboratory_NN data_NNS ,_, were_VBD abstracted_JJ from_IN the_DT medical_JJ
          record_NN into_IN a_DT standardized_JJ data_NN collection_NN form_NN for_IN which_WDT
          all_DT variables_NNS and_CC criteria_NNS were_VBD defined_VBN ._. Additional_JJ data_NNS ,_,
          including_VBG information_NN on_IN antibiotic_JJ use_NN ,_, treatment_NN
          modalities_NNS (_( pulmonary_JJ artery_NN catheter_NN [_NN PAC_NNP ]_NN use_NN ,_,
          ventilator_NN support_NN ,_, pressor_NN support_NN ,_, albumin_NN infusion_NN ,_,
          het-astarch_JJ ,_, and_CC dextran_NN )_) ,_, complications_NNS (_( ARDS_NNP ,_, renal_JJ
          failure_NN ,_, liver_NN failure_NN ,_, DIC_NNP ,_, and_CC shock_NN )_) ,_, and_CC associated_VBN
          outcomes_NNS ,_, were_VBD abstracted_JJ 28_CD days_NNS after_IN the_DT first_JJ onset_NN
          of_IN severe_JJ sepsis_NN or_CC at_IN the_DT time_NN of_IN death_NN or_CC hospital_NN
          discharge_NN ,_, whichever_WDT came_VBD first_JJ ._. Hospital_NN length_NN of_IN stay_NN
          (_( LOS_NNP )_) before_IN and_CC after_IN the_DT onset_NN of_IN severe_JJ sepsis_NN and_CC
          total_JJ hospital_NN charge_NN were_VBD obtained_VBN from_IN the_DT unified_JJ
          Academic_NNP Medical_NNP Center_NNP Consortium_NNP hospital_NN billing_NN
          database_NN ._.
          We_PRP calculated_VBD the_DT patient_NN 's_POS Charlson_NNP comorbidity_NN score_NN
          [_NN 25_CD ]_NN ;_: a_DT higher_JJR score_NN reflects_VBZ greater_JJR comorbidity_NN ._. We_PRP
          also_RB obtained_VBD information_NN on_IN discharge_NN diagnosis-relative_JJ
          groups_NNS (_( DRGs_NNP )_) and_CC DRG_NNP weight_NN ._. The_DT current_JJ generation_NN of_IN
          DRGs_NNP was_VBD originally_RB based_VBN on_IN ICD-_NNP 9_CD -_: CM_NNP and_CC takes_VBZ into_IN
          consideration_NN operations_NNS ,_, complications_NNS ,_, and_CC
          comorbidities_NNS ._. Each_DT DRG_NNP was_VBD preassigned_JJ an_DT average_JJ LOS_NNP
          and_CC reimbursement_NN rate_NN by_IN the_DT US_NNP Health_NNP Care_NNP Financing_NNP
          Administration_NNP ._. The_DT higher_JJR the_DT DRG_NNP weight_NN ,_, the_DT higher_JJR the_DT
          level_NN of_IN reimbursement_NN ._.
        
        
          Analyses_NNS
          Because_IN the_DT sampling_VBG fractions_NNS from_IN different_JJ strata_NN
          varied_VBD [_NN 22_CD ]_NN ,_, individual_JJ cases_NNS carried_VBD different_JJ weight_NN
          [_NN 23_CD ]_NN and_CC all_DT calculations_NNS ,_, including_VBG means_VBZ and_CC
          proportions_NNS ,_, were_VBD performed_VBN using_VBG appropriate_JJ case_NN
          weights_NNS ._.
          We_PRP compared_VBD the_DT proportion_NN of_IN sepsis_NN patients_NNS
          receiving_VBG each_DT intervention_NN therapy_NN and_CC then_RB the_DT
          proportion_NN with_IN complications_NNS among_IN eight_CD academic_JJ
          centers_NNS ,_, using_VBG weighted_JJ χ_NN 2_CD statistics_NNS ._. We_PRP also_RB calculated_VBD
          the_DT ratio_NN of_IN the_DT highest_JJS to_TO lowest_JJS proportion_NN for_IN each_DT
          intervention_NN and_CC complication_NN ._. Multivariate_NNP comparisons_NNS
          were_VBD made_VBN using_VBG generalized_JJ linear_JJ modeling_NN ,_, with_IN
          post-onset_JJ LOS_NNP and_CC hospital_NN charges_NNS as_IN dependent_JJ
          variables_NNS and_CC study_NN center_NN (_( coded_VBN as_IN dummy_JJ variables_NNS )_) as_IN
          the_DT main_JJ covariate_NN ,_, adjusting_VBG for_IN age_NN ,_, sex_NN ,_, Charlson_NNP
          comorbidity_NN score_NN ,_, discharge_NN DRG_NNP weight_NN ,_, organ_NN
          dysfunction_NN (_( ARDS_NNP ,_, uncontrolled_JJ hemorrhage_NN ,_, moderate_JJ or_CC
          severe_JJ liver_NN disease_NN ,_, or_CC acute_JJ renal_JJ failure_NN )_) ,_, and_CC
          service_NN (_( surgical_JJ versus_CC medical_JJ )_) at_IN onset_NN of_IN sepsis_NN ._. The_DT
          same_JJ adjustment_NN of_IN variables_NNS was_VBD applied_VBN in_IN logistic_JJ
          regression_NN models_NNS to_TO compare_VB the_DT likelihood_NN that_IN a_DT sepsis_NN
          patient_NN at_IN a_DT particular_JJ center_NN received_VBD an_DT intervention_NN
          and_CC experienced_VBD a_DT complication_NN ,_, arbitrarily_RB choosing_VBG
          center_NN #_# 1_CD as_IN the_DT reference_NN center_NN ._. Because_IN patients_NNS
          within_IN the_DT same_JJ center_NN could_MD share_VB some_DT common_JJ
          characteristics_NNS ,_, generalized_JJ estimating_NN equation_NN
          regression_NN models_NNS were_VBD used_VBN to_TO perform_VB the_DT analyses_NNS on_IN
          the_DT comparisons_NNS of_IN resource_NN use_NN between_IN patients_NNS with_IN and_CC
          without_IN use_NN of_IN modalities_NNS ._. The_DT 
          r_LS 2_CD value_NN was_VBD calculated_VBN for_IN each_DT
          model_NN ._. All_DT analyses_NNS were_VBD performed_VBN using_VBG the_DT SAS_NNP
          statistical_JJ package_NN (_( SAS_NNP Institute_NNP ,_, Inc_NNP ._. ,_, Cary_NNP ,_, NC_NNP ,_, USA_NNP )_)
          [_NN 26_CD ]_NN ._.
        
      
      
        Results_NNS
        
          Variation_NNP in_IN resource_NN use_NN
          There_EX was_VBD significant_JJ variation_NN in_IN mean_NN total_JJ charges_NNS
          among_IN admissions_NNS with_IN severe_JJ sepsis_NN among_IN the_DT study_NN
          centers_NNS ,_, varying_VBG from_IN $_$ 65_CD 162_CD (_( median_JJ $_$ 42_CD 802_CD )_) to_TO $_$ 244_CD
          293_CD (_( median_JJ $_$ 181_CD 758_CD ;_: Table_NNP 2_LS )_) ._. The_DT mean_JJ post-onset_JJ LOS_NNP
          varied_VBD from_IN 16_CD ._. 1_LS days_NNS to_TO 24_CD ._. 8_CD days_NNS (_( median_JJ range_NN 9_CD -_: 16_CD
          days_NNS )_) among_IN centers_NNS ._. Other_JJ measures_NNS of_IN resource_NN
          utilization_NN including_VBG total_JJ LOS_NNP and_CC LOS_NNP in_IN the_DT ICU_NNP were_VBD
          also_RB significantly_RB different_JJ across_IN centers_NNS ,_, with_IN means_NNS
          of_IN 22_CD ._. 7_CD -_: 36_CD ._. 9_CD days_NNS and_CC 5_CD ._. 0_CD -_: 17_CD ._. 8_CD days_NNS ,_, respectively_RB ._. After_IN
          adjusting_VBG for_IN age_NN ,_, sex_NN ,_, Charlson_NNP comorbidity_NN score_NN ,_,
          discharge_NN DRG_NNP weight_NN ,_, organ_NN dysfunction_NN ,_, and_CC service_NN at_IN
          onset_NN of_IN sepsis_NN ,_, the_DT variations_NNS in_IN mean_NN total_JJ charges_NNS and_CC
          post-onset_JJ LOS_NNP remained_VBD significant_JJ ,_, ranging_VBG from_IN $_$ 69_CD 429_CD
          ±_NN $_$ 9562_CD to_TO $_$ 237_CD 898_CD ±_NN $_$ 12_CD 129_CD ,_, and_CC from_IN 15_CD ._. 9_CD ±_NN 2_CD ._. 0_CD days_NNS
          to_TO 24_CD ._. 2_LS ±_NN 1_CD ._. 8_CD days_NNS ,_, respectively_RB (_( Table_NNP 3_LS )_) ._.
        
        
          Variation_NNP in_IN therapeutic_JJ modality_NN use_NN
          Interventions_NNP used_VBD frequently_RB after_IN the_DT onset_NN of_IN
          severe_JJ sepsis_NN included_VBD PACs_NNPS (_( 19_CD ._. 4_LS %_NN )_) ,_, ventilator_NN support_NN
          (_( 21_CD ._. 8_CD %_NN )_) ,_, pressor_NN support_NN (_( 45_CD ._. 8_CD %_NN )_) ,_, and_CC albumin_NN infusion_NN
          (_( 14_CD ._. 4_LS %_NN ;_: Table_NNP 4_LS )_) ._. Although_IN there_EX were_VBD variations_NNS across_IN
          medical_JJ centers_NNS for_IN each_DT therapeutic_JJ modality_NN ,_, variation_NN
          profiles_NNS differed_VBD substantially_RB among_IN the_DT modalities_NNS ._.
          Modalities_NNP with_IN moderate_JJ variation_NN profiles_NNS among_IN the_DT
          eight_CD participating_VBG centers_NNS included_VBD PACs_NNPS (_( varied_VBD
          4_CD ._. 0_CD -_: fold_VB ,_, 95_CD %_NN confidence_NN interval_NN [_NN CI_NNP ]_NN of_IN 2_CD ._. 6_CD -_: fold_VB to_TO
          6_CD ._. 4_CD -_: fold_VB ;_: range_NN 8_CD ._. 7_CD %_NN to_TO 35_CD ._. 1_LS %_NN )_) ,_, ventilator_NN support_NN
          (_( varied_VBD 3_CD ._. 2_CD -_: fold_VB ,_, 95_CD %_NN CI_NNP 2_CD ._. 1_CD -_: fold_VB to_TO 4_CD ._. 9_CD -_: fold_VB ;_: range_NN
          11_CD ._. 5_LS %_NN to_TO 36_CD ._. 4_LS %_NN )_) ,_, and_CC albumin_NN infusion_NN within_IN 24_CD hours_NNS
          after_IN sepsis_NN onset_NN (_( varied_VBD 4_CD ._. 9_CD -_: fold_VB ,_, 95_CD %_NN CI_NNP 2_CD ._. 2_CD -_: fold_VB to_TO
          10_CD ._. 9_CD -_: fold_VB ;_: range_NN 6_CD ._. 0_CD %_NN to_TO 29_CD ._. 1_LS %_NN )_) ._. In_IN contrast_NN ,_, use_NN of_IN
          pressor_NN support_NN varied_VBD only_RB 1_CD ._. 9_CD -_: fold_VB (_( 95_CD %_NN CI_NNP 1_CD ._. 4_CD -_: fold_VB to_TO
          2_CD ._. 6_CD -_: fold_VB )_) across_IN centers_NNS ,_, ranging_VBG from_IN 31_CD ._. 4_LS %_NN to_TO 60_CD ._. 4_LS %_NN ,_,
          and_CC antibiotics_NNS given_VBN within_IN 24_CD hours_NNS after_IN onset_NN had_VBD the_DT
          least_JJS variation_NN ,_, of_IN 1_CD ._. 1_CD -_: fold_VB (_( 95_CD %_NN CI_NNP 1_CD ._. 0_CD -_: fold_VB to_TO
          1_CD ._. 1_CD -_: fold_VB ]_NN and_CC ranging_VBG from_IN 87_CD ._. 0_CD %_NN to_TO 98_CD ._. 5_LS %_NN ._. Use_NN of_IN
          hetastarch_NN and_CC use_NN of_IN dextran_NN within_IN 24_CD hours_NNS after_IN onset_NN
          in_IN sepsis_NN patients_NNS were_VBD the_DT least_JJS common_JJ therapeutic_JJ
          modalities_NNS among_IN the_DT eight_CD centers_NNS ,_, with_IN ranges_NNS of_IN 0_CD -_: 6_CD ._. 8_CD %_NN
          and_CC 0_CD -_: 6_CD ._. 2_LS %_NN ,_, respectively_RB ._. Of_IN patients_NNS receiving_VBG pressors_NNS
          within_IN 24_CD hours_NNS after_IN sepsis_NN onset_NN ,_, 28_CD ._. 3_LS %_NN received_VBD
          low-dose_JJ dopamine_NN only_RB (_( <_NN 5_CD μg_NN /_NN kg_NN per_IN min_NN )_) ;_: the_DT
          proportion_NN varied_VBD 7_CD -_: fold_VB (_( 95_CD %_NN CI_NNP 2_CD ._. 4_CD -_: fold_VB to_TO 20_CD ._. 8_CD -_: fold_VB )_)
          across_IN centers_NNS ,_, ranging_VBG from_IN 6_CD ._. 4_CD %_NN in_IN center_NN 5_CD to_TO 44_CD ._. 8_CD %_NN in_IN
          center_NN 1_CD (_( data_NNS not_RB shown_VBN )_) ._.
          The_DT results_NNS of_IN models_NNS adjusting_VBG for_IN age_NN ,_, sex_NN ,_, Charlson_NNP
          comorbidity_NN score_NN ,_, discharge_NN DRG_NNP weight_NN ,_, organ_NN
          dysfunction_NN ,_, and_CC service_NN at_IN onset_NN of_IN sepsis_NN are_VBP shown_VBN in_IN
          Fig_NNP ._. 1_LS ._. Centers_NNPS that_WDT had_VBD rates_NNS significantly_RB higher_JJR than_IN
          the_DT reference_NN center_NN were_VBD centers_NNS 3_CD ,_, 4_CD ,_, 5_CD ,_, 6_CD ,_, and_CC 8_CD for_IN
          PAC_NNP use_NN ;_: centers_NNS 2_CD ,_, 3_CD ,_, 4_CD ,_, 5_CD ,_, and_CC 8_CD for_IN ventilator_NN
          support_NN ;_: center_NN 7_CD for_IN pressor_NN support_NN ;_: and_CC centers_NNS 2_CD ,_, 7_CD ,_,
          and_CC 8_CD for_IN albumin_NN infusion_NN ._. In_IN contrast_NN ,_, significantly_RB
          lower_JJR rates_NNS for_IN antibiotic_JJ use_NN within_IN 24_CD hours_NNS after_IN
          onset_NN were_VBD identified_VBN in_IN centers_NNS 3_CD ,_, 4_CD ,_, 5_CD ,_, 6_CD ,_, 7_CD ,_, and_CC
          8_CD ._.
        
        
          Variation_NNP in_IN outcomes_NNS
          Among_IN all_DT patients_NNS with_IN severe_JJ sepsis_NN ,_, frequent_JJ
          complications_NNS included_VBD shock_NN (_( 45_CD ._. 4_LS %_NN )_) ,_, renal_JJ failure_NN
          (_( 19_CD ._. 7_CD %_NN )_) ,_, CNS_NNP dysfunction_NN (_( 18_CD ._. 9_CD %_NN )_) ,_, liver_NN failure_NN (_( 12_CD ._. 2_LS %_NN )_) ,_,
          DIC_NNP (_( 10_CD ._. 3_LS %_NN )_) ,_, ARDS_NNP (_( 9_CD ._. 1_LS %_NN )_) ,_, and_CC death_NN (_( 30_CD ._. 0_CD %_NN )_) within_IN 28_CD
          days_NNS after_IN sepsis_NN onset_NN (_( Table_NNP 5_LS )_) ._. There_EX was_VBD significant_JJ
          variation_NN in_IN each_DT type_NN of_IN complication_NN across_IN the_DT eight_CD
          centers_NNS ,_, with_IN ranges_NNS of_IN 23_CD ._. 9_CD -_: 70_CD ._. 0_CD %_NN for_IN shock_NN ,_, 9_CD ._. 5_CD -_: 35_CD ._. 0_CD %_NN
          for_IN renal_JJ failure_NN ,_, 0_CD ._. 3_CD -_: 37_CD ._. 5_LS %_NN for_IN CNS_NNP dysfunction_NN ,_,
          4_CD ._. 1_CD -_: 27_CD ._. 9_CD %_NN for_IN liver_NN failure_NN ,_, 5_CD ._. 5_CD -_: 15_CD ._. 0_CD %_NN for_IN DIC_NNP ,_, 2_CD ._. 8_CD -_: 21_CD ._. 8_CD %_NN
          for_IN ARDS_NNP ,_, and_CC 19_CD ._. 3_LS -_: 49_CD ._. 1_LS %_NN for_IN 28_CD -_: day_NN mortality_NN rate_NN ._.
          Figure_NN 2_CD shows_VBZ the_DT results_NNS of_IN differences_NNS in_IN rates_NNS of_IN
          sepsis_NN complications_NNS adjusted_VBN for_IN age_NN ,_, sex_NN ,_, Charlson_NNP
          comorbidity_NN score_NN ,_, discharge_NN DRG_NNP weight_NN ,_, organ_NN
          dysfunction_NN ,_, and_CC service_NN at_IN onset_NN of_IN sepsis_NN ._. Analysis_NNP of_IN
          the_DT 28_CD -_: day_NN in-hospital_JJ adjusted_VBN mortality_NN rates_NNS revealed_VBD
          3_CD -_: fold_VB variability_NN among_IN centers_NNS ._. Compared_VBN with_IN the_DT
          reference_NN center_NN ,_, higher_JJR rates_NNS were_VBD found_VBN for_IN ARDS_NNP among_IN
          one_CD center_NN (_( C_NNP 8_CD )_) ,_, for_IN renal_JJ failure_NN among_IN five_CD centers_NNS
          (_( C_NNP 3_CD ,_, C_NNP 4_CD ,_, C_NNP 5_CD ,_, C_NNP 7_CD ,_, and_CC C_NNP 8_CD )_) ,_, for_IN liver_NN failure_NN among_IN one_CD
          center_NN (_( C_NNP 4_LS )_) ,_, for_IN shock_NN among_IN six_CD centers_NNS (_( C_NNP 3_CD ,_, C_NNP 4_CD ,_, C_NNP 5_CD ,_, C_NNP 6_CD ,_,
          C_NNP 7_CD ,_, and_CC C_NNP 8_CD )_) ,_, and_CC for_IN 28_CD -_: day_NN mortality_NN among_IN four_CD centers_NNS
          (_( C_NNP 3_CD ,_, C_NNP 6_CD ,_, C_NNP 7_CD ,_, and_CC C_NNP 8_CD )_) ._.
          Also_RB ,_, a_DT significant_JJ inverse_NN correlation_NN was_VBD seen_VBN
          between_IN antibiotic_JJ use_NN within_IN 24_CD hours_NNS after_IN onset_NN of_IN
          episode_NN and_CC the_DT 28_CD -_: day_NN mortality_NN rates_NNS (_( 
          r_LS 2_CD =_SYM 0_CD ._. 72_CD ;_: 
          P_NN =_SYM 0_CD ._. 01_CD ;_: Fig_NNP ._. 3_LS )_) ._. This_DT correlation_NN
          remained_VBD significant_JJ even_RB after_IN excluding_VBG patients_NNS with_IN
          '_POS do_VBP not_RB resuscitate_VB '_POS orders_NNS (_( 
          r_LS 2_CD =_SYM 0_CD ._. 63_CD ;_: 
          P_NN =_SYM 0_CD ._. 02_CD )_) ._. Significant_JJ associations_NNS
          were_VBD not_RB found_VBN between_IN 28_CD -_: day_NN mortality_NN and_CC the_DT use_NN of_IN
          other_JJ modalities_NNS across_IN the_DT eight_CD centers_NNS (_( data_NNS not_RB
          shown_VBN )_) ._.
        
        
          Relation_NNP between_IN resource_NN use_NN and_CC modalities_NNS
          Comparisons_NNP of_IN resource_NN use_NN among_IN patients_NNS treated_VBN
          with_IN specific_JJ modalities_NNS and_CC those_DT who_WP were_VBD not_RB showed_VBN
          that_DT administration_NN of_IN antibiotics_NNS within_IN 24_CD hours_NNS after_IN
          sepsis_NN onset_NN had_VBD no_DT impact_NN on_IN any_DT of_IN the_DT LOS_NNP categories_NNS ,_,
          but_CC was_VBD associated_VBN with_IN total_JJ and_CC daily_JJ hospital_NN charges_NNS
          (_( Table_NNP 6_CD )_) ._. Use_NN of_IN other_JJ modalities_NNS (_( including_VBG albumin_NN
          infusion_NN )_) was_VBD associated_VBN with_IN increased_VBN resource_NN use_NN for_IN
          daily_JJ hospital_NN charges_NNS ._. Total_JJ hospital_NN charges_NNS and_CC LOS_NNP in_IN
          the_DT ICU_NNP were_VBD significantly_RB higher_JJR among_IN patients_NNS who_WP were_VBD
          given_VBN pressor_NN support_NN and_CC /_NN or_CC albumin_NN infusion_NN after_IN onset_NN
          of_IN sepsis_NN as_IN compared_VBN with_IN those_DT who_WP were_VBD not_RB ._. Increased_VBN
          post-onset_JJ LOS_NNP and_CC LOS_NNP in_IN the_DT ICU_NNP were_VBD associated_VBN with_IN
          use_NN of_IN PACs_NNPS ._. No_DT associations_NNS were_VBD found_VBN between_IN total_JJ LOS_NNP
          and_CC the_DT modalities_NNS studied_VBN ._.
        
      
      
        Discussion_NNP
        Overall_RB ,_, we_PRP found_VBD moderate_JJ variation_NN in_IN resource_NN and_CC
        therapeutic_JJ modality_NN use_NN among_IN patients_NNS with_IN severe_JJ sepsis_NN
        in_IN academic_JJ centers_NNS ._. In_IN general_JJ ,_, this_DT variation_NN had_VBD little_JJ
        relationship_NN to_TO clinical_JJ outcomes_NNS ,_, although_IN clinical_JJ
        outcomes_NNS varied_VBD substantially_RB between_IN the_DT centers_NNS ._. The_DT
        exception_NN is_VBZ that_IN ,_, even_RB adjusting_VBG for_IN potential_JJ
        confounders_NNS ,_, early_JJ antibiotic_JJ therapy_NN was_VBD associated_VBN with_IN a_DT
        lower_JJR 28_CD -_: day_NN mortality_NN rate_NN ._. Increased_VBN use_NN of_IN some_DT of_IN the_DT
        therapeutic_JJ modalities_NNS was_VBD associated_VBN with_IN greater_JJR resource_NN
        utilization_NN ._.
        Prior_RB studies_VBZ have_VBP shown_VBN variability_NN in_IN the_DT use_NN of_IN
        therapeutic_JJ modalities_NNS (_( including_VBG PACs_NNPS ,_, ventilator_NN ,_, and_CC
        intravenous_JJ vasoactive_JJ and_CC inotropic_JJ agents_NNS )_) among_IN ICU_NNP
        patients_NNS [_NN 21_CD 27_CD ]_NN and_CC different_JJ impacts_NNS on_IN outcomes_NNS and_CC
        use_NN of_IN hospital_NN resources_NNS associated_VBN with_IN these_DT treatments_NNS
        [_NN 16_CD 17_CD 18_CD 28_CD 29_CD ]_NN ._. In_IN general_JJ ,_, with_IN the_DT exception_NN of_IN the_DT
        recent_JJ trial_NN demonstrating_VBG benefit_NN of_IN early_JJ goal-directed_JJ
        treatment_NN involving_VBG oxygenation_NN (_( including_VBG ventilatory_NN
        support_NN if_IN necessary_JJ )_) and_CC blood_NN pressure_NN (_( including_VBG
        intravenous_JJ pressors_NNS if_IN necessary_JJ )_) [_NN 30_CD ]_NN ,_, few_JJ data_NNS are_VBP
        available_JJ that_WDT demonstrate_VBP that_IN these_DT modalities_NNS improve_VBP
        outcomes_NNS ._.
        Colloids_NNP and_CC crystalloid_NN are_VBP equally_RB effective_JJ in_IN
        restoring_VBG tissue_NN perfusion_NN in_IN patients_NNS with_IN septic_JJ shock_NN [_NN
        31_CD ]_NN ._. However_RB ,_, the_DT choice_NN of_IN fluid_NN has_VBZ considerable_JJ cost_NN
        implications_NNS :_: colloids_NNS cost_VBP more_JJR for_IN volume_NN replacement_NN ._.
        Largely_RB inappropriate_JJ use_NN of_IN colloids_NNS was_VBD found_VBN in_IN a_DT survey_NN
        of_IN academic_JJ health_NN centers_NNS despite_IN guidelines_NNS from_IN a_DT US_NNP
        hospital_NN consortium_NN recommending_VBG that_IN colloids_NNS be_VB used_VBN in_IN
        hemorrhagic_JJ shock_NN only_RB until_IN blood_NN products_NNS become_VBP
        available_JJ ,_, and_CC in_IN nonhemorrhagic_JJ shock_NN only_RB if_IN an_DT initial_JJ
        infusion_NN with_IN crystalloid_NN is_VBZ insufficient_JJ [_NN 32_CD 33_CD ]_NN ._. A_DT
        recent_JJ systematic_JJ review_NN of_IN randomized_JJ controlled_VBN trials_NNS
        comparing_VBG colloids_NNS and_CC crystalloid_NN solutions_NNS for_IN volume_NN
        replacement_NN found_VBD that_DT resuscitation_NN with_IN colloids_NNS in_IN
        critically_RB ill_JJ patients_NNS was_VBD actually_RB associated_VBN with_IN an_DT
        increased_VBN risk_NN of_IN mortality_NN [_NN 10_CD ]_NN ._.
        In_IN addition_NN ,_, vasopressors_NNS have_VBP been_VBN recommended_VBN to_TO
        achieve_VB end-points_JJ of_IN hemodynamic_JJ ,_, and_CC normal_JJ or_CC
        supranormal_NN oxygen_NN transport_NN variables_NNS in_IN sepsis_NN patients_NNS
        who_WP remain_VBP hypotensive_JJ despite_IN adequate_JJ volume_NN therapy_NN ._.
        However_RB ,_, after_IN reviewing_VBG the_DT literature_NN on_IN the_DT use_NN of_IN
        vasopressors_NNS in_IN patients_NNS with_IN sepsis_NN syndrome_NN ,_, Rudis_NNP and_CC
        colleagues_NNS [_NN 13_CD ]_NN found_VBD that_DT catecholamine_NN therapy_NN
        resulting_VBG in_IN increased_VBN hemodynamic_JJ and_CC oxygen_NN transport_NN
        measures_NNS did_VBD not_RB change_VB the_DT overall_JJ mortality_NN ,_, with_IN the_DT
        exception_NN of_IN two_CD instances_NNS in_IN which_WDT epinephrine_NN
        (_( adrenaline_NN )_) and_CC norepinephrine_NN (_( noradrenaline_NN )_) were_VBD given_VBN
        alone_RB after_IN volume_NN repletion_NN ._. The_DT results_NNS from_IN a_DT recent_JJ
        trial_NN of_IN low-dose_JJ dopamine_NN in_IN critically_RB ill_JJ patients_NNS ,_, who_WP
        had_VBD systemic_JJ inflammatory_JJ response_NN syndrome_NN and_CC were_VBD at_IN
        risk_NN for_IN renal_JJ failure_NN ,_, did_VBD not_RB show_VB benefit_NN in_IN renal_JJ
        protection_NN and_CC survival_NN from_IN the_DT treatment_NN [_NN 34_CD ]_NN ._.
        However_RB ,_, a_DT very_RB recent_JJ trial_NN of_IN early_JJ goal-directed_JJ therapy_NN
        in_IN treatment_NN of_IN sepsis_NN did_VBD demonstrate_VB substantial_JJ
        improvement_NN in_IN outcome_NN [_NN 30_CD ]_NN ._.
        Another_DT technology_NN is_VBZ monitoring_VBG central_JJ pressures_NNS by_IN
        PAC_NNP ,_, which_WDT is_VBZ often_RB used_VBN in_IN ICUs_NNP to_TO assess_VB the_DT effect_NN of_IN
        pharmacotherapy_NN on_IN the_DT cardiac_JJ index_NN in_IN patients_NNS with_IN
        septic_JJ shock_NN ._. This_DT is_VBZ done_VBN even_RB though_IN the_DT efficacy_NN of_IN the_DT
        PAC_NNP has_VBZ never_RB been_VBN demonstrated_VBN convincingly_RB in_IN a_DT large_JJ
        randomized_JJ controlled_VBN trial_NN ._. A_DT number_NN of_IN randomized_JJ
        controlled_VBN trials_NNS have_VBP examined_VBN the_DT effectiveness_NN of_IN PACs_NNPS
        or_CC PAC-guided_NNP strategies_NNS in_IN sepsis_NN patients_NNS [_NN 16_CD 17_CD 18_CD 19_CD
        20_CD 35_CD 36_CD ]_NN and_CC other_JJ specific_JJ patient_NN groups_NNS [_NN 29_CD 37_CD 38_CD 39_CD
        40_CD 41_CD 42_CD 43_CD ]_NN ,_, with_IN conflicting_JJ results_NNS ._. A_DT recent_JJ case_NN mix_NN
        adjusted_VBD observational_NN study_NN of_IN a_DT large_JJ sample_NN of_IN ICU_NNP
        patients_NNS found_VBD that_IN PAC_NNP use_NN was_VBD associated_VBN with_IN increased_VBN
        risk_NN for_IN mortality_NN and_CC resource_NN use_NN [_NN 28_CD ]_NN ._.
        Mechanical_NNP ventilation_NN in_IN patients_NNS with_IN ARDS_NNP has_VBZ been_VBN
        reported_VBN to_TO be_VB associated_VBN with_IN pneumonia_NN and_CC lung_NN injury_NN [_NN
        44_CD 45_CD 46_CD 47_CD ]_NN ._. Properly_NNP constructed_VBN trials_NNS are_VBP still_RB
        needed_VBN to_TO define_VB the_DT best_JJS use_NN of_IN mechanical_JJ ventilation_NN in_IN
        sepsis_NN ,_, although_IN early_JJ ventilatory_NN support_NN was_VBD a_DT component_NN
        of_IN the_DT recent_JJ early_JJ goal-directed_JJ intervention_NN by_IN Rivers_NNP
        and_CC coworkers_NNS [_NN 30_CD ]_NN ._.
        Use_NN of_IN some_DT therapeutic_JJ modalities_NNS does_VBZ appear_VB
        correlated_JJ with_IN organizational_JJ characteristics_NNS ._. For_IN
        example_NN ,_, results_NNS from_IN a_DT national_JJ ICU_NNP survey_NN conducted_VBN by_IN
        Greoger_NNP and_CC colleagues_NNS [_NN 21_CD ]_NN showed_VBD that_IN more_JJR technologies_NNS
        were_VBD used_VBN in_IN surgical_JJ units_NNS as_IN compared_VBN with_IN other_JJ units_NNS ,_,
        as_RB well_RB as_IN in_IN larger_JJR versus_CC smaller_JJR hospitals_NNS ,_, and_CC in_IN
        university-affiliated_JJ facilities_NNS ._. In_IN addition_NN ,_, a_DT large_JJ
        prospective_JJ multicenter_NN study_NN evaluated_VBD the_DT differences_NNS in_IN
        ICU_NNP characteristics_NNS and_CC performance_NN among_IN teaching_NN and_CC
        nonteaching_VBG hospitals_NNS [_NN 48_CD ]_NN ._. The_DT results_NNS of_IN that_DT study_NN
        revealed_VBD more_RBR frequent_JJ use_NN of_IN monitoring_VBG and_CC therapeutic_JJ
        interventions_NNS ,_, and_CC greater_JJR resource_NN utilization_NN in_IN teaching_NN
        hospital_NN ICUs_NNP ._. Also_RB ,_, a_DT recent_JJ report_NN from_IN a_DT large_JJ
        retrospective_NN database_NN study_NN of_IN ICU_NNP patients_NNS [_NN 27_CD ]_NN
        confirmed_VBD that_IN organizational_JJ characteristics_NNS of_IN ICUs_NNP were_VBD
        associated_VBN with_IN variation_NN in_IN PAC_NNP use_NN ._. In_IN addition_NN ,_, that_DT
        report_NN indicated_VBD that_IN economic_JJ incentives_NNS and_CC insurance_NN
        coverage_NN ,_, as_RB well_RB as_IN clinical_JJ variables_NNS ,_, were_VBD associated_VBN
        with_IN PAC_NNP use_NN ._. Similarly_RB ,_, much_JJ of_IN the_DT variation_NN in_IN resource_NN
        use_NN and_CC modality_NN use_NN across_IN centers_NNS in_IN the_DT present_JJ study_NN
        may_MD not_RB be_VB due_JJ to_TO patient-related_JJ factors_NNS ,_, but_CC rather_RB to_TO
        organizational_JJ factors_NNS and_CC physician_NN beliefs_NNS ._.
        We_PRP did_VBD find_VB a_DT number_NN of_IN relationships_NNS between_IN modality_NN
        use_NN and_CC resource_NN utilization_NN ._. In_IN particular_JJ ,_, there_EX were_VBD
        associations_NNS between_IN LOS_NNP in_IN the_DT ICU_NNP and_CC use_NN of_IN PACs_NNPS ,_,
        pressor_NN support_NN ,_, and_CC albumin_NN infusion_NN ._. These_DT may_MD probably_RB
        be_VB accounted_VBN for_IN in_IN part_NN by_IN the_DT fact_NN that_IN patients_NNS with_IN
        longer_RBR LOS_NNP in_IN the_DT ICU_NNP were_VBD more_RBR likely_JJ to_TO be_VB treated_VBN with_IN
        supportive_JJ technologies_NNS ._. In_IN general_JJ ,_, however_RB ,_, modalities_NNS
        with_IN higher_JJR variation_NN profiles_NNS reflect_VBP areas_NNS of_IN greater_JJR
        disagreement_NN in_IN terms_NNS of_IN treatment_NN decision-making_NN ._. Such_JJ
        areas_NNS may_MD be_VB fertile_JJ for_IN additional_JJ investigation_NN ._.
        It_PRP is_VBZ striking_JJ that_DT delay_NN in_IN antibiotic_JJ therapy_NN was_VBD
        associated_VBN with_IN a_DT higher_JJR mortality_NN rate_NN and_CC that_IN some_DT
        delays_NNS were_VBD present_JJ in_IN this_DT very_RB ill_JJ population_NN ._. Delays_NNP are_VBP
        common_JJ in_IN American_JJ medicine_NN [_NN 49_CD ]_NN ,_, even_RB in_IN urgent_JJ
        situations_NNS such_JJ as_IN treatment_NN of_IN life-threatening_JJ laboratory_NN
        abnormalities_NNS [_NN 50_CD ]_NN ._. Although_IN we_PRP do_VBP not_RB know_VB the_DT causes_NNS
        of_IN delays_NNS in_IN antibiotic_JJ initiation_NN ,_, they_PRP appeared_VBD more_RBR
        common_JJ in_IN some_DT institutions_NNS than_IN in_IN others_NNS ._. We_PRP speculate_VBP
        that_IN some_DT may_MD have_VB occurred_VBN because_IN of_IN problems_NNS related_VBN to_TO
        crowding_VBG ;_: for_IN example_NN ,_, emergency_NN rooms_NNS or_CC ICUs_NNP might_MD have_VB
        been_VBN full_JJ ,_, resulting_VBG in_IN delayed_VBN transfer_VB ,_, or_CC the_DT clinical_JJ
        importance_NN of_IN changes_NNS in_IN vital_JJ signs_NNS might_MD not_RB have_VB been_VBN
        recognized_VBN ._. Approaches_NNP such_JJ as_IN protocols_NNS for_IN early_JJ
        recognition_NN and_CC treatment_NN of_IN severe_JJ sepsis_NN ,_, and_CC
        facilitation_NN of_IN medication_NN orders_NNS that_WDT are_VBP really_RB needed_VBN
        urgently_RB may_MD be_VB helpful_JJ ._. Guidelines_NNS for_IN the_DT management_NN of_IN
        severe_JJ sepsis_NN are_VBP probably_RB most_RBS applicable_JJ for_IN certain_JJ
        treatment_NN modalities_NNS ,_, such_JJ as_IN PACs_NNPS ,_, albumin_NN ,_, dextran_NN ,_, and_CC
        hetastarch_NN ._. Even_RB use_NN of_IN organ_NN failure_NN treatment_NN modalities_NNS
        such_JJ as_IN ventilator_NN support_NN and_CC renal_JJ replacement_NN therapies_NNS
        might_MD be_VB different_JJ if_IN such_JJ guidelines_NNS were_VBD developed_VBN ._.
        An_DT important_JJ underlying_VBG issue_NN is_VBZ why_WRB variation_NN occurs_VBZ [_NN
        51_CD 52_CD ]_NN ._. It_PRP should_MD not_RB be_VB surprising_JJ that_IN it_PRP is_VBZ present_JJ in_IN
        this_DT domain_NN ,_, because_IN the_DT pioneering_JJ work_NN of_IN Wennberg_NNP [_NN 52_CD ]_NN
        identified_VBD variation_NN across_IN a_DT broad_JJ array_NN of_IN domains_NNS ._. One_CD
        of_IN the_DT major_JJ causes_NNS of_IN variation_NN is_VBZ probably_RB physician_NN
        uncertainty_NN regarding_VBG what_WP interventions_NNS are_VBP truly_RB
        beneficial_JJ ,_, and_CC clinician_NN beliefs_NNS ,_, where_WRB training_NN occurred_VBD ,_,
        and_CC regional_JJ practices_NNS probably_RB also_RB play_VB roles_NNS ._.
        Uncertainty_NN may_MD be_VB especially_RB problematic_JJ in_IN conditions_NNS
        such_JJ as_IN sepsis_NN ,_, in_IN which_WDT mortality_NN is_VBZ high_JJ ,_, and_CC clinicians_NNS
        strongly_RB want_VBP to_TO do_VB everything_NN possible_JJ ._. Variation_NNP is_VBZ
        likely_JJ to_TO diminish_VB as_IN more_JJR evidence_NN becomes_VBZ available_JJ and_CC
        is_VBZ brought_VBN to_TO the_DT point_NN of_IN care_NN ._. Analysis_NNP of_IN variation_NN can_MD
        be_VB very_RB useful_JJ for_IN identifying_VBG areas_NNS of_IN high_JJ uncertainty_NN [_NN
        52_CD ]_NN ._.
        This_DT study_NN has_VBZ a_DT number_NN of_IN limitations_NNS ._. We_PRP had_VBD
        information_NN only_RB on_IN hospital_NN charges_NNS ,_, rather_RB than_IN hospital_NN
        costs_NNS ._. We_PRP did_VBD not_RB have_VB information_NN on_IN organizational_JJ
        variables_NNS such_JJ as_IN organizational_JJ setting_NN ,_, staffing_NN ,_, or_CC
        leadership_NN of_IN practices_NNS ,_, and_CC the_DT study_NN included_VBD only_RB
        academic_JJ centers_NNS ._. Also_RB ,_, our_PRP$ data_NNS did_VBD not_RB include_VB the_DT
        indications_NNS for_IN use_NN of_IN therapeutic_JJ modalities_NNS ._.
        In_IN conclusion_NN ,_, significant_JJ variations_NNS were_VBD present_JJ in_IN
        hospital_NN resource_NN use_NN and_CC patient_NN outcome_NN among_IN sepsis_NN
        patients_NNS across_IN eight_CD academic_JJ medical_JJ centers_NNS ._. In_IN general_JJ ,_,
        variation_NN in_IN therapeutic_JJ modality_NN use_NN did_VBD not_RB correlate_VBP
        with_IN clinical_JJ outcomes_NNS ,_, suggesting_VBG that_IN some_DT use_NN of_IN these_DT
        modalities_NNS may_MD be_VB of_IN limited_JJ value_NN ,_, and_CC that_IN further_JJ
        evaluation_NN of_IN these_DT modalities_NNS is_VBZ warranted_VBN ._. The_DT exception_NN
        was_VBD that_DT delay_NN in_IN giving_VBG antibiotics_NNS to_TO sepsis_NN patients_NNS was_VBD
        associated_VBN with_IN a_DT higher_JJR 28_CD -_: day_NN mortality_NN rate_NN ._. Approaches_NNP
        to_TO eliminate_VB these_DT delays_NNS may_MD improve_VB outcomes_NNS ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Key_JJ messages_NNS
        •_NN Moderate_NNP variation_NN in_IN resource_NN use_NN and_CC use_NN of_IN
        technologies_NNS was_VBD present_JJ in_IN treatment_NN of_IN severe_JJ sepsis_NN
        among_IN academic_JJ centers_NNS
        •_NN This_DT variation_NN presisted_JJ even_RB after_IN adjusting_VBG for_IN
        potential_JJ confounders_NNS
        •_NN Increased_VBN use_NN of_IN some_DT therapeutic_JJ modalities_NNS such_JJ as_IN
        albumin_NN infusion_NN was_VBD associated_VBN with_IN greater_JJR resource_NN
        utilization_NN
        •_NN Among_IN therapeutic_JJ modalities_NNS ,_, only_RB early_JJ antibiotic_JJ
        use_NN was_VBD associated_VBN with_IN lower_JJR 28_CD -_: day_NN mortality_NN
        •_NN Taken_VBN together_RB ,_, these_DT data_NNS suggest_VBP that_IN some_DT
        therapeutic_JJ modalities_NNS may_MD be_VB of_IN limited_JJ value_NN in_IN sepsis_NN
        treatment_NN and_CC that_IN further_JJ evaluation_NN is_VBZ warranted_VBN
      
      
        Abbreviations_NNP
        ARDS_NNP =_SYM acute_JJ respiratory_JJ distress_NN syndrome_NN ;_: CI_NNP =_SYM
        confidence_NN interval_NN ;_: CNS_NNP =_SYM central_JJ nervous_JJ system_NN ;_: DIC_NNP =_SYM
        disseminated_VBN intravascular_NN coagulation_NN ;_: DRG_NNP =_SYM
        diagnosis-relative_JJ group_NN ;_: ICU_NNP =_SYM intensive_JJ care_NN unit_NN ;_: LOS_NNP =_SYM
        length_NN of_IN stay_NN ;_: PAC_NNP =_SYM pulmonary_JJ artery_NN catheter_NN ._.
      
    
  
